Your browser is no longer supported. Please, upgrade your browser.
Settings
ABEO Abeona Therapeutics Inc. daily Stock Chart
ABEO [NASD]
Abeona Therapeutics Inc.
Index- P/E- EPS (ttm)-0.96 Insider Own33.50% Shs Outstand48.54M Perf Week-1.52%
Market Cap345.60M Forward P/E- EPS next Y-1.40 Insider Trans0.00% Shs Float31.88M Perf Month-2.60%
Income-45.00M PEG- EPS next Q-0.42 Inst Own73.00% Short Float28.53% Perf Quarter-31.87%
Sales5.30M P/S65.21 EPS this Y-2.50% Inst Trans0.08% Short Ratio13.47 Perf Half Y-48.96%
Book/sh3.14 P/B2.27 EPS next Y-19.70% ROA-26.40% Target Price26.33 Perf Year-53.31%
Cash/sh2.31 P/C3.08 EPS next 5Y- ROE-27.70% 52W Range6.26 - 22.00 Perf YTD-0.28%
Dividend- P/FCF- EPS past 5Y52.10% ROI-16.40% 52W High-67.00% Beta2.14
Dividend %- Quick Ratio11.10 Sales past 5Y-28.30% Gross Margin- 52W Low15.99% ATR0.47
Employees42 Current Ratio11.10 Sales Q/Q750.00% Oper. Margin- RSI (14)49.87 Volatility4.31% 6.16%
OptionableYes Debt/Eq0.00 EPS Q/Q-159.60% Profit Margin- Rel Volume0.23 Prev Close7.12
ShortableYes LT Debt/Eq0.00 EarningsFeb 08 AMC Payout- Avg Volume675.29K Price7.26
Recom1.90 SMA204.18% SMA50-5.42% SMA200-44.57% Volume114,938 Change1.97%
Oct-12-18Initiated Mizuho Buy $17
Jun-05-18Initiated Seaport Global Securities Buy $29
Nov-08-17Initiated SunTrust Buy $26
Oct-16-17Reiterated H.C. Wainwright Buy $20 → $30
Oct-11-17Reiterated Cantor Fitzgerald Overweight $21 → $34
Oct-10-17Initiated Citigroup Buy $32
Oct-05-17Reiterated Maxim Group Buy $17 → $35
Sep-15-17Initiated RBC Capital Mkts Outperform $23
Jul-18-17Reiterated Maxim Group Buy $14 → $17
Jun-22-17Resumed Jefferies Buy $22
Jan-06-17Initiated Jefferies Buy
Sep-29-16Reiterated Maxim Group Buy $8 → $14
Dec-16-15Initiated Maxim Group Buy $6
Jul-20-15Initiated MLV & Co Buy $15
Jan-08-19 01:00PM  Abeona Therapeutics Strengthens Financial Leadership with New Executive Appointments GlobeNewswire
Dec-25-18 06:24AM  How Should Investors Feel About Abeona Therapeutics Inc.s (NASDAQ:ABEO) CEO Pay? Simply Wall St.
Dec-13-18 03:03AM  Is Abeona Therapeutics Inc (ABEO) A Good Stock To Buy? Insider Monkey -8.45%
Dec-11-18 08:52AM  Abeona Therapeutics (ABEO) in Focus: Stock Moves 5.5% Higher Zacks -11.54%
Dec-10-18 08:44AM  Why Abeona Therapeutics (ABEO) Could Be Positioned for a Slump Zacks +5.50%
Dec-06-18 12:30PM  Abeona Therapeutics Details Pathway for Advancing Lead Clinical Programs and Unveils New Cystic Fibrosis Program Born from Next Generation AIM Vector Platform at 2018 R&D Day GlobeNewswire +7.38%
Dec-03-18 08:27AM  Moving Average Crossover Alert: Abeona Therapeutics Zacks
Nov-29-18 08:45AM  Abeona Therapeutics to Host R&D Day on December 6, 2018 GlobeNewswire
Nov-27-18 08:00AM  Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire -7.14%
Nov-26-18 04:30PM  Abeona Therapeutics Announces CEO Transition GlobeNewswire
Nov-13-18 08:45AM  Abeona Announces Participation at the Jefferies 2018 London Healthcare Conference GlobeNewswire
07:26AM  Edited Transcript of ABEO earnings conference call or presentation 12-Nov-18 3:00pm GMT Thomson Reuters StreetEvents
Nov-09-18 05:35PM  Abeona Therapeutics (ABEO) Reports Q3 Loss, Tops Revenue Estimates Zacks -5.26%
04:27PM  Abeona Therapeutics: 3Q Earnings Snapshot Associated Press
04:20PM  Abeona Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights GlobeNewswire
Nov-07-18 11:18AM  What Kind Of Share Price Volatility Should You Expect For Abeona Therapeutics Inc (NASDAQ:ABEO)? Simply Wall St.
Nov-05-18 07:00AM  REGENXBIO and Abeona Therapeutics Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector PR Newswire
07:00AM  Abeona Therapeutics and REGENXBIO Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector GlobeNewswire
Oct-18-18 08:03AM  Abeona Therapeutics Appoints João Siffert, M.D. Head of Research and Development and Chief Medical Officer GlobeNewswire
Oct-16-18 07:55AM  Investor Expectations to Drive Momentum within Cincinnati Bell, Hooker Furniture, AgroFresh Solutions, Forward Industries, Abeona Therapeutics, and Sientra Discovering Underlying Factors of Influence GlobeNewswire
Sep-28-18 08:45AM  Abeona Announces Participation at Upcoming Conferences GlobeNewswire
Sep-14-18 08:45AM  When Will Abeona Therapeutics Inc (NASDAQ:ABEO) Become Profitable? Simply Wall St.
Sep-12-18 08:45AM  Abeona Therapeutics Announces Authorization to Commence Phase 1/2 Gene Therapy Clinical Study for Patients with MPS IIIB in Spain GlobeNewswire
Sep-04-18 08:45AM  Abeona Announces Participation at Upcoming Conferences GlobeNewswire
Aug-28-18 11:55PM  Edited Transcript of ABEO earnings conference call or presentation 10-Aug-18 2:00pm GMT Thomson Reuters StreetEvents +6.01%
Aug-17-18 07:50AM  Factors of Influence in 2018, Key Indicators and Opportunity within AgroFresh Solutions, SMART SAND INC, Advantage Oil & Gas, Abeona Therapeutics, B. Riley Financial, and Audentes Therapeutics New Research Emphasizes Economic Growth GlobeNewswire
Aug-09-18 07:55PM  Abeona Therapeutics (ABEO) Reports Q2 Loss, Lags Revenue Estimates Zacks
06:50PM  Abeona Therapeutics: 2Q Earnings Snapshot Associated Press
04:20PM  Abeona Therapeutics Reports Second Quarter 2018 Financial Results and Business Highlights GlobeNewswire
Jul-26-18 08:30AM  Abeona Therapeutics Announces Leadership Appointments with Max Colao as Chief Commercial Officer GlobeNewswire
Jul-11-18 10:17AM  Implied Volatility Surging for Abeona Therapeutics (ABEO) Stock Options Zacks
Jul-05-18 07:35AM  Free Technical Reports on 22nd Century Group and Three Additional Biotech Equities ACCESSWIRE
Jun-18-18 04:21PM  Newman Ferrara LLP Announces Corporate Governance Investigation of Abeona Therapeutics Inc. ABEO Business Wire
Jun-07-18 07:47AM  57% Sales Growth, Top-Notch Partners At Overlooked Gene and Cell Therapy Issue ORGS ACCESSWIRE
Jun-06-18 08:45AM  Abeona Therapeutics Announces Upcoming Presentation at Jefferies 2018 Global Healthcare Conference GlobeNewswire
Jun-05-18 03:21PM  Abeona Therapeutics Has First-Mover Potential In Rare Diseases, Seaport Says In Bullish Initiation Benzinga +6.92%
07:20AM  Free Technical Research on Versartis and Three More Biotech Equities ACCESSWIRE
Jun-04-18 02:30PM  9 Stocks Poised for Healthy Long-Term Gains Investopedia -11.29%
May-31-18 08:45AM  Abeona Therapeutics Announces Opening of Commercial Gene & Cell Therapy Manufacturing Facility in Ohio GlobeNewswire -5.60%
08:30AM  Analysis: Positioning to Benefit within Avadel Pharmaceuticals, Abeona Therapeutics, BanColombia S.A, Aercap Holdings N.V, Kite Realty Group Trust, and Credicorp Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
May-18-18 05:30PM  Here's Why Abeona Therapeutics Stock Dropped 12% Today Motley Fool -12.00%
09:25AM  Abeona Therapeutics Provides Clinical Update on MPS IIIA Gene Therapy Trial at the 21st Annual ASGCT Meeting GlobeNewswire
May-17-18 09:20AM  Abeona Reports Update from EB-101 Gene Therapy in Epidermolysis Bullosa at 21st Annual ASGCT Meeting GlobeNewswire
May-15-18 06:02PM  Edited Transcript of ABEO earnings conference call or presentation 14-May-18 2:00pm GMT Thomson Reuters StreetEvents
May-14-18 12:19PM  Abeona Therapeutics Inc (NASDAQ:ABEO): Does The -41.52% Earnings Drop Reflect A Longer Term Trend? Simply Wall St. +6.36%
08:15AM  Abeona Therapeutics Announces Appointment of Stefano Buono and Richard Van Duyne to its Board of Directors GlobeNewswire
May-11-18 08:25AM  Abeona Therapeutics: 1Q Earnings Snapshot Associated Press
08:16AM  Abeona Therapeutics Reports First Quarter 2018 Financial Results and Business Highlights GlobeNewswire
May-08-18 08:15AM  Abeona Therapeutics Announces Upcoming Presentations GlobeNewswire
Apr-27-18 11:10AM  Kensho's genetic engineering index CNBC Videos
Apr-24-18 07:40AM  Wired News European Medicines Agency Granted Orphan Drug Designation for Abeonas ABO-202 Gene Therapy Program in Batten Disease ACCESSWIRE -7.75%
Apr-23-18 08:16AM  Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA GlobeNewswire
08:15AM  Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA GlobeNewswire
Apr-20-18 08:16AM  Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease GlobeNewswire
Apr-12-18 09:27PM  When Will Abeona Therapeutics Inc (NASDAQ:ABEO) Breakeven? Simply Wall St.
Apr-10-18 08:38AM  Why Abeona Therapeutics (ABEO) Could Be Positioned for a Slump Zacks +7.25%
08:30AM  Todays Research Reports on Trending Tickers: Abeona Therapeutics and Spark Therapeutics ACCESSWIRE
Apr-06-18 07:50AM  Report: Exploring Fundamental Drivers Behind Haverty Furniture Companies, Scholastic, Dover, MYR Group, Abeona Therapeutics, and U.S. Global Investors New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Apr-02-18 08:16AM  Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer GlobeNewswire
06:00AM  7 Stocks for the Biotech Takeover Wave Investopedia
Mar-27-18 07:21PM  Edited Transcript of ABEO earnings conference call or presentation 27-Mar-18 2:00pm GMT Thomson Reuters StreetEvents -6.98%
07:00AM  Abeona Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-20-18 02:58PM  15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies TheStreet.com
Mar-16-18 05:34PM  Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights GlobeNewswire
05:10PM  Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights GlobeNewswire
Mar-15-18 08:45AM  Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease GlobeNewswire
Feb-22-18 07:35AM  New Research Coverage Highlights Western Alliance, Matson, Vail Resorts, Abeona Therapeutics, Under Armour, and AGNC Investment Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire +14.10%
Feb-21-18 08:45AM  Abeona Therapeutics Announces Upcoming Conference Participation GlobeNewswire
Feb-12-18 08:45AM  Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-202 Gene Therapy Program in Infantile Batten Disease GlobeNewswire -10.48%
Feb-08-18 02:00PM  Abeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIA GlobeNewswire -14.56%
Feb-07-18 07:01PM  Why Abeona Therapeutics Jumped 14% on Wednesday Motley Fool +14.11%
04:42PM  Traders Need to Adapt to a New Reality TheStreet.com
08:46AM  Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial GlobeNewswire
08:45AM  Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial GlobeNewswire
Feb-02-18 08:54AM  Abeona Therapeutics Announces Upcoming Presentations at the 14th Annual WORLDSymposium GlobeNewswire
08:46AM  Abeona Therapeutics Announces Upcoming Presentations at the 14th Annual WORLDSymposium GlobeNewswire
Jan-29-18 09:45AM  UPDATE: Abeona shares rise 10% on 'regenerative medicine advanced therapy' designation from FDA MarketWatch
08:46AM  Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa GlobeNewswire
08:45AM  Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa GlobeNewswire
Jan-02-18 10:35AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Abeona Therapeutics Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire +8.52%
Dec-28-17 11:44AM  ETFs with exposure to Abeona Therapeutics, Inc. : December 28, 2017 Capital Cube
Dec-27-17 08:56AM  Abeona Therapeutics, Inc. :ABEO-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 Capital Cube
Dec-20-17 08:46AM  Abeona Therapeutics Enrolls First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIB GlobeNewswire
08:45AM  Abeona Therapeutics Enrolls First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIB GlobeNewswire
Dec-19-17 01:37PM  7 Stocks Ready to Jump Another 30% in 2018 InvestorPlace
Nov-29-17 08:10AM  Edited Transcript of ABEO earnings conference call or presentation 20-Nov-17 3:00pm GMT Thomson Reuters StreetEvents
Nov-27-17 07:31AM  Abeona Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ABEO-US : November 27, 2017 Capital Cube
Nov-22-17 07:20AM  Featured Company News - Celldex Starts Phase-2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma ACCESSWIRE
Nov-17-17 01:33PM  Abeona Therapeutics, Inc. Value Analysis (NASDAQ:ABEO) : November 17, 2017 Capital Cube
Nov-16-17 07:05AM  Abeona Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ABEO-US : November 16, 2017 Capital Cube
Nov-15-17 08:31AM  Abeona Therapeutics reports 3Q loss Associated Press +10.93%
08:26AM  Abeona Reports Third Quarter 2017 Financial Results and Recent Business Highlights GlobeNewswire
08:25AM  Abeona Reports Third Quarter 2017 Financial Results and Recent Business Highlights GlobeNewswire
Nov-13-17 08:45AM  Abeona Management to Present at Multiple Conferences in November GlobeNewswire
Nov-09-17 08:46AM  Abeona Enrolls First Subject in Spain in Ongoing Phase 1/2 Clinical Trial in MPS IIIA GlobeNewswire
08:45AM  Abeona Enrolls First Subject in Spain in Ongoing Phase 1/2 Clinical Trial in MPS IIIA GlobeNewswire
Oct-20-17 01:19PM  Market Still Lacks Ability to Find Volatility TheStreet.com +7.04%
Oct-19-17 09:39AM  Abeona Announces Closing of $92 Million Underwritten Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Oct-17-17 09:24AM  Abeona Shares Higher After Pricing Stock Offering -- Biotech Movers TheStreet.com +7.19%
Oct-16-17 09:45PM  Abeona Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. Abeona Therapeutics Inc. also has a license agreement with REGENXBIO Inc. to NAV AAV9 vector for the treatment of Sanfilippo syndrome type A (MPS IIIA), Sanfilippo syndrome type B (MPS IIIB), Infantile Batten, and Juvenile Batten diseases. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.